Table 3.
Predictive ability of different dichotomized models
| Model | Low risk group (n, %) | High risk group (n, %) | HR (95% CI) | Pre-test probability (%) | Post-test probability (%) low risk group | Post-test probability (%) high risk group |
|---|---|---|---|---|---|---|
| Whole population | ||||||
| 12-SNP GRS | 0–6 (n = 497, 47.3%) | 7–13 (n = 554, 52.7%) | 2.06 (1.41–2.99) | 12.0 | 8.0 (5.7–10.4) | 15.5 (12.5–18.5) |
| 8-SNP GRS | 0–4 (n = 507, 48.2%) | 5–11 (n = 544, 51.8%) | 1.94 (1.34–2.81) | 12.0 | 8.3 (5.9–10.7) | 15.4 (12.4–18.5) |
| 5-SNP GRS | 0–2 (n = 456, 43.4%) | 3–7 (n = 595, 56.6%) | 1.61 (1.11–2.34) | 12.0 | 9.2 (6.6–11.9) | 14.1 (11.3–16.9) |
| Males | ||||||
| 12-SNP GRS | 0–6 (n = 235, 45.5%) | 7–13 (n = 282, 54.5%) | 2.42 (1.39–4.21) | 12.6 | 7.2 (3.9–10.5) | 17.0 (12.6–21.4) |
| 8-SNP GRS | 0–4 (n = 236, 45.6%) | 5–11 (n = 281, 54.4%) | 2.42 (1.39–4.21) | 12.6 | 7.2 (3.9–10.5) | 17.1 (12.7–21.5) |
| 5-SNP GRS | 0–2 (n = 208, 40.2%) | 3–6 (n = 309, 59.8%) | 1.60 (0.94–2.71) | 12.6 | 9.6 (5.6–13.6) | 14.6 (10.6–18.5) |
| Females | ||||||
| 12-SNP GRS | 0–6 (n = 262, 49.1%) | 7–13 (n = 272, 50.9%) | 1.78 (1.06–2.98) | 11.4 | 8.8 (5.4–12.2) | 14.0 (9.9–18.1) |
| 8-SNP GRS | 0–4 (n = 271, 50.7%) | 5–10 (n = 263, 49.3%) | 1.59 (0.95–2.64) | 11.4 | 9.2 (5.8–12.7) | 13.7 (9.5–17.8) |
| 5-SNP GRS | 0–2 (n = 248, 46.4%) | 5–11 (n = 286, 53.6%) | 1.62 (0.96–2.73) | 11.4 | 8.9 (5.3–12.4) | 13.6 (9.7–17.6) |
| Unprovoked VTE | ||||||
| 12-SNP GRS | 0–6 (n = 303, 48.9%) | 7–13 (n = 316, 51.1%) | 2.29 (1.43–3.68) | 13.1 | 8.3 (5.2–11.3) | 17.7 (13.5–21.9) |
| 8-SNP GRS | 0–4 (n = 309, 49.9%) | 5–11 (n = 310, 50.1%) | 2.83 (1.73–4.61) | 13.1 | 7.1 (4.3–10.0) | 19.0 (14.7–23.4) |
| 5-SNP GRS | 0–2 (n = 279, 45.1%) | 3–7 (n = 340, 54.9%) | 2.24 (1.38–3.63) | 13.1 | 8.2 (5.0-11.5) | 17.1 (13.1–21.1) |
| Provoked VTE | ||||||
| 12-SNP GRS | 0–6 (n = 194, 44.9%) | 7–13 (n = 238, 55.1%) | 1.70 (0.92–3.17) | 13.1 | 7.7 (4.0-11.5) | 12.6 (8.4–16.8) |
| 8-SNP GRS | 0–4 (n = 198, 45.8%) | 5–11 (n = 234, 54.2%) | 1.07 (0.59–1.92) | 13.1 | 10.1 (5.9–14.3) | 10.7 (6.7–14.6) |
| 5-SNP GRS | 0–2 (n = 177, 41.0%) | 3–7 (n = 255, 59.0%) | 0.96 (0.53–1.73) | 13.1 | 10.7 (6.2–15.3) | 10.2 (6.5–13.9) |
Models were calculated by summing the number of risk alleles for different SNPs. The sum is dichotomized into ‘low’ and ‘high’ risk groups (Univariate analyses)
12-SNP GRS: [FII (rs1799963), FV (rs6025), ABO (rs8176719), ApoM (rs805297), F11 (rs2036914), FGG (rs2066865), MRPL37 (rs10888838), THBD (rs1042580), A2M (rs9939609), FTO (rs9939609), PAI-1 (rs1799889), TFAM (rs1937)]]. 8-SNP GRS: [FII (rs1799963), FV (rs6025), ABO (rs8176719), ApoM (rs805297), F11 (rs2036914), FGG (rs2066865), PAI-1 (rs1799889), TFAM (rs1937)]
5-SNP GRS, previously described by Van Hylckama et al. (2014): [FII (rs1799963), FV (rs6025), ABO (rs8176719), F11 (rs2036914), FGG (rs2066865)]
HR hazard ratio of recurrent VTE, Pre-test probability risk of recurrent VTE before SNPs model, Post-test probability risk of recurrent VTE after SNPs model, n number of risk alleles, Unprovoked VTE VTE patients with no acquired risk factors for VTE and no malignancy